JP2019515033A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019515033A5 JP2019515033A5 JP2019507069A JP2019507069A JP2019515033A5 JP 2019515033 A5 JP2019515033 A5 JP 2019515033A5 JP 2019507069 A JP2019507069 A JP 2019507069A JP 2019507069 A JP2019507069 A JP 2019507069A JP 2019515033 A5 JP2019515033 A5 JP 2019515033A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutical composition
- day
- composition according
- ester
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 16
- 150000002148 esters Chemical class 0.000 claims description 6
- 239000000651 prodrug Substances 0.000 claims description 6
- 229940002612 prodrug Drugs 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 201000011452 Adrenoleukodystrophy Diseases 0.000 claims description 2
- 208000010796 X-linked adrenoleukodystrophy Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662326436P | 2016-04-22 | 2016-04-22 | |
| US62/326,436 | 2016-04-22 | ||
| PCT/US2017/029120 WO2017185087A1 (en) | 2016-04-22 | 2017-04-24 | Use of thyroid beta-agonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019515033A JP2019515033A (ja) | 2019-06-06 |
| JP2019515033A5 true JP2019515033A5 (enExample) | 2020-06-11 |
| JP6931042B2 JP6931042B2 (ja) | 2021-09-01 |
Family
ID=60116400
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019507069A Active JP6931042B2 (ja) | 2016-04-22 | 2017-04-24 | 甲状腺ベータアゴニストの使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US11351183B2 (enExample) |
| EP (1) | EP3445373B1 (enExample) |
| JP (1) | JP6931042B2 (enExample) |
| KR (1) | KR102407059B1 (enExample) |
| AU (1) | AU2017252126B2 (enExample) |
| BR (1) | BR112018071586A2 (enExample) |
| CA (1) | CA3021681C (enExample) |
| ES (1) | ES2992773T3 (enExample) |
| MX (1) | MX385085B (enExample) |
| WO (1) | WO2017185087A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017252126B2 (en) | 2016-04-22 | 2023-02-09 | Metabasis Therapeutics, Inc. | Use of thyroid beta-agonists |
| EA202091979A1 (ru) | 2018-03-22 | 2021-06-22 | Вайкинг Терапьютикс, Инк. | Кристаллические формы и способы получения кристаллических форм соединения |
| EP4775207A2 (en) | 2018-12-05 | 2026-07-15 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis |
| US11752161B2 (en) | 2020-03-27 | 2023-09-12 | Gannex Pharma Co., Ltd. | Pharmaceutical compositions, method of making and method of using thereof |
| EP4161925A4 (en) | 2020-06-09 | 2024-09-04 | Viking Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER DISEASES |
| JP2025520449A (ja) * | 2022-06-15 | 2025-07-03 | バイキング セラピューティクス，インコーポレーテッド | Ｘ－ａｌｄ治療のための甲状腺ベータ作動薬投与計画 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040091455A1 (en) | 2002-10-31 | 2004-05-13 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration |
| CA2543132A1 (en) | 2003-10-23 | 2005-05-19 | Celgene Corporation | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain |
| EP2428516A1 (en) | 2003-11-19 | 2012-03-14 | Metabasis Therapeutics, Inc. | Novel phosphorus-containing thyromimetics |
| EP1930046A1 (en) | 2004-12-08 | 2008-06-11 | Sirion Therapeutics, Inc. | Retinol binding protein and transthyretin modulators for treating diabetes |
| US20090232879A1 (en) | 2005-05-26 | 2009-09-17 | Metabasis Therapeutics, Inc. | Thyromimetics for the Treatment of Fatty Liver Diseases |
| RU2007148927A (ru) * | 2005-05-26 | 2009-07-10 | Метабэйзис Терапьютикс, Инк. (Us) | Новые тиреомиметики, содержащие фосфиновую кислоту |
| JPWO2007097289A1 (ja) | 2006-02-20 | 2009-07-16 | 武田薬品工業株式会社 | 新規医薬 |
| US20110071208A1 (en) | 2009-06-05 | 2011-03-24 | Protiva Biotherapeutics, Inc. | Lipid encapsulated dicer-substrate interfering rna |
| WO2011038207A1 (en) | 2009-09-25 | 2011-03-31 | Metabasis Therapeutics, Inc. | Phosphorus-containing thyroid hormone receptor agonists and methods of use |
| EP2723756B1 (en) | 2011-06-21 | 2020-03-11 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibition of expression of apolipoprotein c-iii (apoc3) genes |
| WO2014178892A1 (en) * | 2013-05-03 | 2014-11-06 | Scanlan Thomas S | Use of sobetirome in the treatment of x-linked adrenolenoleukodystrophy |
| PE20180021A1 (es) | 2015-02-20 | 2018-01-09 | Univ Oregon Health & Science | Derivados de sobetiroma |
| WO2017148801A1 (en) | 2016-02-29 | 2017-09-08 | Philip Morris Products S.A. | Hinge-lid container and blank |
| AU2017252126B2 (en) | 2016-04-22 | 2023-02-09 | Metabasis Therapeutics, Inc. | Use of thyroid beta-agonists |
| CN109641003A (zh) | 2016-04-22 | 2019-04-16 | 维京治疗股份有限公司 | 甲状腺β-激动剂的应用 |
| MX382313B (es) | 2016-05-18 | 2025-03-13 | Univ Oregon Health & Science | Derivados del sobetiroma. |
-
2017
- 2017-04-24 AU AU2017252126A patent/AU2017252126B2/en active Active
- 2017-04-24 CA CA3021681A patent/CA3021681C/en active Active
- 2017-04-24 US US16/095,228 patent/US11351183B2/en active Active
- 2017-04-24 WO PCT/US2017/029120 patent/WO2017185087A1/en not_active Ceased
- 2017-04-24 ES ES17786798T patent/ES2992773T3/es active Active
- 2017-04-24 BR BR112018071586-7A patent/BR112018071586A2/pt not_active Application Discontinuation
- 2017-04-24 KR KR1020187033713A patent/KR102407059B1/ko active Active
- 2017-04-24 MX MX2018012900A patent/MX385085B/es unknown
- 2017-04-24 JP JP2019507069A patent/JP6931042B2/ja active Active
- 2017-04-24 EP EP17786798.3A patent/EP3445373B1/en active Active
-
2022
- 2022-05-06 US US17/738,621 patent/US11951114B2/en active Active
-
2024
- 2024-03-05 US US18/595,919 patent/US12440502B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020097577A5 (enExample) | ||
| JP2017518334A5 (enExample) | ||
| JP2018534348A5 (enExample) | ||
| JP2015078230A5 (enExample) | ||
| JP2018111728A5 (enExample) | ||
| CN109415406A (zh) | 羊毛甾醇前药化合物及其制备方法和应用 | |
| RU2018114447A (ru) | Введение дейтерированных усилителей cftr | |
| JP2017513836A5 (enExample) | ||
| JP2016515561A5 (enExample) | ||
| MX2020010300A (es) | Sales monoacidas de 6-aminoisoquinolinas y usos de las mismas. | |
| JP2018531941A5 (enExample) | ||
| JP2015155440A5 (enExample) | ||
| JP2019516739A5 (enExample) | ||
| JP2017505285A5 (enExample) | ||
| CN108026053A8 (zh) | 作为mIDH1抑制剂的稠合的咪唑类化合物 | |
| JP2017533930A5 (enExample) | ||
| JP2018530578A5 (enExample) | ||
| JP2014218522A5 (enExample) | ||
| JP2016534081A5 (ja) | ゾレドロン酸の増強された経口バイオアベイラビリティーを有する経口剤形を調製する方法 | |
| JP2017508817A5 (enExample) | ||
| JP2017502074A5 (enExample) | ||
| JP2018521056A5 (enExample) | ||
| JP2018530608A5 (enExample) | ||
| PH12019500618A1 (en) | Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease | |
| JP2018524306A5 (enExample) |